Early diagnosis of AD is a major challenge and current work focuses on the detection of excess of total tau and Aβ in cerebrospinal fluid, and on using imaging of the brain by positron emission tomography and magnetic resonance imaging (MRI) for Aβ plaques (e.g. refs2–4). Here, MAPT is linked to Alzheimer disease.